EmeraldLos Angeles, CA; September - CellKey, a leading provider of innovative bioanalytical solutions, is thrilled to announce the signing of a Memorandum of Understanding (MOU) with Emerald Cloud Lab (ECL), a pioneer in cloud-based laboratory facilities, to collaborate on the development of a cutting-edge glycoprotein analysis platform. This strategic partnership aims to revolutionize glycosylation studies, essential for diagnosing and treating cancer and various other diseases, as evidenced by the groundbreaking work of the recent Nobel laureate in Chemistry at Stanford University.

The collaboration unites CellKey's proprietary glycoprotein analysis powered by data foundry platform, the SpAC9 Data Foundry, with ECL's state-of-the-art cloud-based lab facilities. This integration will empower researchers worldwide to remotely access the SpAC9 data foundry and conduct advanced glycoprotein and protein analysis experiments through the ECL platform, eliminating the need to be physically present in the laboratory.

Glycoproteins play a crucial role in understanding the intricate mechanisms underlying human diseases, making their analysis paramount for advancing therapeutic interventions. The SpAC9 data foundry, developed by CellKey, leverages mass spectrometry instruments to offer a comprehensive range of analytical solutions, including glycan profiling, glycopeptide identification, glycosylation site mapping, and quantification of glycoprotein heterogeneity. Researchers will now have the means to gain deep insights into the structures and functions of glycoproteins, accelerating groundbreaking discoveries and advancements in disease treatment.

Key features and benefits of the SpAC9 data foundry include:

  • Comprehensive Analysis: The SpAC9 data foundry provides researchers with a comprehensive suite of analytical tools, offering a thorough examination of glycoprotein attributes crucial to their functions and implications in disease
  • High-throughput Capabilities: Optimized for high-throughput analysis, the platform enables researchers to process large-scale datasets efficiently and rapidly, enhancing its analytical speed up to 100 times faster than a conventional analytics solution.
  • Customization Options: Understanding the unique requirements of research projects, the SpAC9 data foundry offers flexible customization options to tailor experimental designs and achieve specific research objectives effectively.
  • User-Friendly Interface: The platform's intuitive user interface ensures accessibility for researchers with varying levels of expertise in glycoprotein analysis, fostering collaboration and knowledge exchange.
  • Robust Data Interpretation: Extracting meaningful insights from complex glycoprotein datasets becomes seamless with the SpAC9 data foundry, providing comprehensive data visualizations and dashboard.

The partnership between CellKey and ECL represents a significant step forward in the field of glycoprotein analysis. By combining CellKey's expertise in glycoproteomics and proteomics with ECL's advanced cloud-based laboratory infrastructure, researchers worldwide will have unparalleled access to cutting-edge technologies without the constraints of physical laboratory presence.

"We are thrilled about this partnership with Emerald Cloud Lab," said Dr. Je Min Yoo, the Head of US Research & Business Development at CellKey USA Inc. "The integration of our SpAC9 data foundry with ECL's cloud-based lab facilities will empower researchers globally to unravel the complexities of glycoproteins and make strides in understanding and treating currently incurable diseases."

“The collaboration between Emerald Cloud Lab and CellKey will help us provide new research capabilities to our life science customers and reinforces our commitment to providing researchers with convenient and affordable access to the most advanced lab facilities and equipment worldwide,” said Jennifer Henry-Smith, Senior Vice President of Sales at Emerald Cloud Lab.

About CellKey: CellKey is a leading provider of bioanalytical solutions specializing in glycoprotein analytics. Their innovative SpAC9 data foundry facilitates advanced research into the intricate realm of glycosylation, heralding a path toward groundbreaking advancements in therapeutics.

About Emerald Cloud Lab (ECL): Emerald Cloud Lab (ECL) is a pioneer in providing advanced cloud-based laboratory facilities, offering remote accessibility to scientific research and promoting collaboration on a global scale. ECL's platform enables researchers to conduct experiments efficiently and effortlessly from anywhere in the world.